相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。DPP-4 Inhibitors and Lipids: Systematic Review and Meta-Analysis
Matteo Monami et al.
ADVANCES IN THERAPY (2012)
Safety and tolerability of linagliptin: a pooled analysis of data from randomized controlled trials in 3572 patients with type 2 diabetes mellitus
G. Schernthaner et al.
DIABETES OBESITY & METABOLISM (2012)
Efficacy and safety of saxagliptin in older patients with type 2 diabetes mellitus
Jean Doucet et al.
CURRENT MEDICAL RESEARCH AND OPINION (2011)
Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials
Matteo Monami et al.
CURRENT MEDICAL RESEARCH AND OPINION (2011)
Effects of a long-acting GLP-1 mimetic (PF-04603629) on pulse rate and diastolic blood pressure in patients with type 2 diabetes mellitus
S. M. Gustavson et al.
DIABETES OBESITY & METABOLISM (2011)
Effect of Exenatide on Inflammatory and Oxidative Stress Markers in Patients with Type 2 Diabetes Mellitus
Jin-dan Wu et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2011)
Cardiovascular effects of DPP-4 inhibition: Beyond GLP-1
Gian Paolo Fadini et al.
VASCULAR PHARMACOLOGY (2011)
Inhibition of dipeptidyl peptidase 4 regulates microvascular endothelial growth induced by inflammatory cytokines
Wataru Takasawa et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2010)
DPP-4 Inhibition by Sitagliptin Improves the Myocardial Response to Dobutamine Stress and Mitigates Stunning in a Pilot Study of Patients With Coronary Artery Disease
Philip A. Read et al.
CIRCULATION-CARDIOVASCULAR IMAGING (2010)
Weight Loss, Glycemic Control, and Changes in Cardiovascular Biomarkers in Patients With Type 2 Diabetes Receiving Incretin Therapies or Insulin in a Large Cohort Database
Edward S. Horton et al.
DIABETES CARE (2010)
The Oral Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Increases Circulating Endothelial Progenitor Cells in Patients With Type 2 Diabetes Possible role of stromal-derived factor-1α
Gian Paolo Fadini et al.
DIABETES CARE (2010)
Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population
A. Schweizer et al.
DIABETES OBESITY & METABOLISM (2010)
Dipeptydil peptidase-4 inhibitors in type 2 diabetes: A meta-analysis of randomized clinical trials
M. Monami et al.
NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2010)
Dipeptidyl Peptidase-4 Inhibitors for the Treatment of Type 2 Diabetes Mellitus
Joshua J. Neumiller et al.
PHARMACOTHERAPY (2010)
Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes
Debora Williams-Herman et al.
BMC ENDOCRINE DISORDERS (2010)
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
David Moher et al.
ANNALS OF INTERNAL MEDICINE (2009)
Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin - diabetes control and potential adverse events
Bo Ahren
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM (2009)
Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies
M. R. Law et al.
BMJ-BRITISH MEDICAL JOURNAL (2009)
Primary Prevention of Cardiovascular Mortality and Events With Statin Treatments
Edward J. Mills et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2008)
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes
Steven E. Nissen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure
George G. Sokos et al.
JOURNAL OF CARDIAC FAILURE (2006)
The UKPDS risk engine: a model for the risk of coronary heart disease in Type II diabetes (UKPDS 56)
RJ Stevens et al.
CLINICAL SCIENCE (2001)
分享论文
